About 9,280 results
Open links in new tab
  1. The New England Journal of Medicine | Research & Review Articles …

    3 days ago · The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide …

  2. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based …

    Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …

  3. Current Issue | New England Journal of Medicine

    Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 18).

  4. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

    Dec 11, 2024 · In a phase 3, open-label trial, we enrolled patients with ER-positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer that recurred or …

  5. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...

    Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase …

  6. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

    Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a …

  7. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

    Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl …

  8. Antibiotic Treatment for 7 versus 14 Days in Patients with …

    Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In …

  9. Zongertinib in Previously Treated - The New England Journal of …

    Apr 28, 2025 · Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is …

  10. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis

    Mar 5, 2025 · Bacterial vaginosis affects one third of reproductive-aged women, and recurrence is common. Evidence of sexual exchange of bacterial vaginosis–associated organisms between …